RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

NCT06185400 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

108

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer
ERBB2 Mutation-Related Tumors
ERBB2 Gene Duplication
Disitamab Vedotin

Interventions

DRUG: Disitamab Vedotin
DRUG: third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)
DRUG: pyrotinib

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences